$590m to Moderna from HHS for mRNA ‘flu vax development
"$590m to Moderna from HHS for mRNA ‘flu vax development" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.
Moderna confirms $590M award by U.S. for bird flu vaccine development
Moderna (MRNA) announced ongoing support from the U.S. Department of Health and Human Services, HHS, to accelerate the development of
Bird Flu: US Invests $590 Million to Fast-Track Vaccine Development
The Department of Health and Human Services has granted millions of dollars to Moderna to speed up bird flu vaccine development.
Moderna Secures $590M Funding From U.S. Government for Bird Flu Jab
Moderna MRNA announced that the U.S. government, through the Biomedical Advanced Research and Development Authority (“BARDA”), has awarded the company $590 million to accelerate the development of an mRNA-based vaccine program aimed at preventing the spread of the H5N1 virus,
Moderna Gets $590 Million to Develop Bird Flu Vaccine
The government is working to head off human bird flu infections. The U.S. government has awarded Moderna $590 million to advance the development of its bird flu vaccine, as the country doubles down on efforts to tackle increasing infections in humans.
Moderna Stock Jumps as Biotech Gets $590M From US To Develop Bird-Flu Vaccine
Key Takeaways Moderna received a $590 million award from the U.S. government to speed development of a vaccine that could be used to fight bird flu.The biotech firm's mRNA-1018 candidate posted positive results in a Phase 1/2 study launched in 2023.
Moderna gets $590M from US government for bird flu vaccine
Moderna has been testing an mRNA candidate for influenza viruses like the H5 and H7 strains that are seen as pandemic threats. Others, including GSK and Pfizer, are also at work on similar shots.
Emergent BioSolutions stock reaffirms buy rating on contract modification
H.C. Wainwright & Co. reaffirmed its Buy rating and $15.00 price target for Emergent BioSolutions stock (NYSE:EBS). The ...
TipRanks on MSN5d
Shionogi Secures BARDA Funding for Long-Acting COVID-19 Antiviral Development
Shionogi & Co. has been awarded a $375 million project agreement by the Biomedical Advanced Research and Development ...
cidrap.umn4d
BARDA to fund development of COVID preventive drug
Shionogi will receive $375 million to develop a long-acting protease inhibitor designed to prevent SARS-CoV-2 infection in ...
Business Wire8d
Vaxxas Named Stage Winner of United States’ BARDA Prize to Advance Microarray Patches for Vaccination
Vaxxas, a clinical-stage biotechnology company commercializing a novel high-density microarray patch (HD-MAP) vaccination platform, has been named a C ...
Emergent BioSolutions receives contract option valued at $16.7M
Emergent BioSolutions (EBS) announced that the Biomedical Advanced Research and Development Authority executed a contract modification for the ...
Moderna Announces Updates on Pandemic Influenza Program
Moderna, Inc. (NASDAQ:MRNA) today announced ongoing support from the U.S. Department of Health and Human Services (HHS) to accelerate the development of mRNA-based pandemic influenza vaccines. The ...
The Bakersfield Californian8d
Micron Biomedical Wins $2 Million BARDA Competition for Its Collaboration with Zipcode Bio to ...
Micron Biomedical, a life science company developing the world’s first needle-free technology for drugs and vaccines that is based on dissolvable microarrays, ...